Bibliografia UJ CM

1/3
P. Berlanga, C. Pasqualini, U. Potschger, C. Sanguesa, M.R. Castellani, A. Canete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A[leksandra] Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Castel, D. Valteau-Couanet, R. Ladenstein.
Central nervous system relapse in high-risk stage 4 neuroblastoma : The HR-NBL1/SIOPEN trial experience.
European Journal of Cancer
2021 : Vol. 144, s. 1-8, il., bibliogr. 17 poz., abstr.
Autor korespondencyjny: P. Berlanga.
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.
p-ISSN: 0959-8049
AZ
ORG
AIF
IF: 10.002
Adres url:
Streszczenie w PubMed:
2/3
R. Ladenstein, U. Poetschger, M. Elliot, R. Luksch, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W[alentyna] Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz de Lacerda, M. Beck-Popovic, P. Bician, M. Garami, T. Trahair, P. Ambros, K. Holmes, G. Schreier, M. Gaze, A. Pearson, D. Valteau-Couanet, SIOP Europe Neuroblastoma Grp.
Risk factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN TRIAL.
Bone Marrow Transplantation
2016 : Vol. 51, suppl. 1, s. S46, abstr. O072.
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, Spain, APR 03-06, 2016.
p-ISSN: 0268-3369
SZZ
SIF
3/3
R. Ladenstein, U. Poetschger, R. Luksch, M. Elliot, V. Castel, I. Yaniv, G. Laureys, W[alentyna] Balwierz, H.N. Lode, D. Valteau-Couanet.
Myeloablative therapy (MAT) and immunotherapy (IT) with ch14.18/cho for high risk neuroblastoma: update and news of randomised results from the HR-NBL1/SIOPEN trial.
Pediatric Blood & Cancer
2014 : Vol. 61, Suppl. 2, s. S122-S123, abstr. O-063.
p-ISSN: 1545-5009
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ